In 2022, Kentucky reported the highest cancer incidence rate in the United States, with around 512 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2022.

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity, sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates, and 95% confidence intervals for rates. The USCS data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System (NVSS).

Age standardized rate of cancer incidence, by selected sites of cancer and sex, three-year average, census metropolitan areas.

The number of new cases, age-standardized rates and average age at diagnosis of cancers diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Cancer incidence rates are age-standardized using the direct method and the final 2011 Canadian postcensal population structure. Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In 2023, Hawaii had the lowest death rate from cancer among all U.S. states, with around 119 deaths per 100,000 population. The states with the highest cancer death rates at that time were Kentucky, West Virginia, and Mississippi. This statistic shows cancer death rates in the United States in 2023, by state.

SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

The Latin American country with the highest age-standardized cancer mortality rate in 2022 was Uruguay, with ***** deaths per 100,000 population. Jamaica and Barbados followed, with cancer mortality rates of ***** and *****, respectively. As of that year, breast cancer was the cancer type with the highest incidence rate in Uruguay, as approximately ***** new cases were reported in the country.

In 2022, breast cancer had the rate of incidents among all cancer types in the Middle East and North Africa, at ** new cases per 100,000 people. Trachea, bronchus and lung cancer had the second highest rate in the region. Vaginal, Oropharynx, and penis cancer all had the lowest incidence with a rate of under *** cases per 100,000 people.

Nova Scotia has the highest cancer incidence rate of any province in Canada, followed by Newfoundland and Labrador, and Ontario. However, Nunavut has the highest cancer mortality rate of the provinces. In Nunavut there are around *** deaths from cancer per 100,000 population, compared to a rate of *** deaths per 100,000 in Newfoundland and Labrador.

New cancer cases

As of 2023, there were around *** new cancer cases in Canada per 100,000 population. The most common types of cancer in Canada include lung and bronchus cancer, breast cancer, and prostate cancer. Breast cancer is the most common type of cancer among women, while prostate cancer is the second most common type among men. Men have slightly higher rates of lung and bronchus cancer and colorectal cancer.

Cancer mortality

Lung and bronchus cancers have the highest mortality rate of any cancer in Canada, followed by colorectal and pancreas cancer. Men in Canada have around a **** percent chance of dying as a result of lung and bronchus cancer. The lifetime probability of dying from any cancer type for males in Canada is around ** percent.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

According to Cognitive Market Research, the global Cancer Diagnosis market size was USD 109614.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 32884.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The consumables category is the fastest growing segment of the Cancer Diagnosis industry

Market Dynamics of Cancer Diagnosis Market

Key Drivers for Cancer Diagnosis Market

Increasing Rate of Cancer Diagnostics to Boost Market Growth

The rising global incidence of cancer, which affects millions of people a year, is a primary driver of the need for diagnostic testing. Numerous factors contribute to this tendency, such as the aging population, which increases the risk of developing some cancers in older adults. Changes in lifestyle, including poor eating habits, inactivity, and increased use of alcohol and tobacco, have also contributed to an increase in cancer incidence. Environmental factors, such as exposure to chemicals and hazardous compounds, exacerbate the problem and increase the risk of developing cancer. Therefore, as early detection and diagnosis are becoming more and more important to patients and healthcare professionals, effective cancer diagnostics are essential. The market for cancer diagnostics is expanding as a result of the increased emphasis on prompt and precise cancer detection, which highlights the value of novel diagnostic procedures. For Instance, in 2023, the Pan American Health Organization (PAHO) projects that there will be 20 million new cases and 10 million deaths, and by 2040, nearly 30 million cases will be reported annually.

Innovations in Diagnostic Technologies to Drive Market Growth

The market for cancer diagnostics is expanding as a result of advancements in diagnostic technologies that have greatly improved the precision and effectiveness of cancer detection. For example, non-invasive cancer biomarker identification in physiological fluids is made possible by liquid biopsies, which offer vital insights into tumor dynamics and therapy response. In a similar vein, molecular diagnostics has transformed the detection of particular genetic abnormalities and changes linked to different types of cancer, allowing for more individualized treatment strategies. High-resolution images of tumors are provided by advanced imaging methods like MRI and PET scans, which help with accurate staging and localization. Better patient outcomes result from these technical developments because they increase overall diagnosis accuracy and enable early intervention. The ongoing development of these cutting-edge diagnostic instruments is propelling market expansion and revolutionizing cancer treatment.

Restraint Factor for the Cancer Diagnosis Market

The High Price of Cutting-Edge Diagnostic Technology Will Limit Market Growth

The market for cancer diagnostics is severely hampered by the high price of sophisticated diagnostic tools. Advanced diagnostic instruments, such as molecular tests and imaging technologies, are frequently expensive, which limits healthcare facilities' access to them, especially in settings with limited resources. These institutions' capacity to provide thorough cancer screening and diagnostic services is restricted by this financial barrier, which eventually affects patient outcomes. These financial difficulties are further exacerbated by the costs associated with the development, research, and regulatory approval of new diagnostic instruments. Companies have to spend a lot of money to comply with...

Lung cancer had the highest rate of death among all cancer types worldwide in 2022. In that year, there were around 17 deaths from trachea, bronchus and lung cancer per 100,000 population. The death rate for all cancers was 91.1 per 100,000 population. This statistic shows the rate of cancer deaths worldwide in 2022, by type of cancer.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Population based cancer incidence rates were abstracted from National Cancer Institute, State Cancer Profiles for all available counties in the United States for which data were available. This is a national county-level database of cancer data that are collected by state public health surveillance systems. All-site cancer is defined as any type of cancer that is captured in the state registry data, though non-melanoma skin cancer is not included. All-site age-adjusted cancer incidence rates were abstracted separately for males and females. County-level annual age-adjusted all-site cancer incidence rates for years 2006–2010 were available for 2687 of 3142 (85.5%) counties in the U.S. Counties for which there are fewer than 16 reported cases in a specific area-sex-race category are suppressed to ensure confidentiality and stability of rate estimates; this accounted for 14 counties in our study. Two states, Kansas and Virginia, do not provide data because of state legislation and regulations which prohibit the release of county level data to outside entities. Data from Michigan does not include cases diagnosed in other states because data exchange agreements prohibit the release of data to third parties. Finally, state data is not available for three states, Minnesota, Ohio, and Washington. The age-adjusted average annual incidence rate for all counties was 453.7 per 100,000 persons. We selected 2006–2010 as it is subsequent in time to the EQI exposure data which was constructed to represent the years 2000–2005. We also gathered data for the three leading causes of cancer for males (lung, prostate, and colorectal) and females (lung, breast, and colorectal). The EQI was used as an exposure metric as an indicator of cumulative environmental exposures at the county-level representing the period 2000 to 2005. A complete description of the datasets used in the EQI are provided in Lobdell et al. and methods used for index construction are described by Messer et al. The EQI was developed for the period 2000– 2005 because it was the time period for which the most recent data were available when index construction was initiated. The EQI includes variables representing each of the environmental domains. The air domain includes 87 variables representing criteria and hazardous air pollutants. The water domain includes 80 variables representing overall water quality, general water contamination, recreational water quality, drinking water quality, atmospheric deposition, drought, and chemical contamination. The land domain includes 26 variables representing agriculture, pesticides, contaminants, facilities, and radon. The built domain includes 14 variables representing roads, highway/road safety, public transit behavior, business environment, and subsidized housing environment. The sociodemographic environment includes 12 variables representing socioeconomics and crime. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., L. Messer, K. Rappazzo , C. Gray, S. Grabich , and D. Lobdell. County-level environmental quality and associations with cancer incidence#. Cancer. John Wiley & Sons Incorporated, New York, NY, USA, 123(15): 2901-2908, (2017).

Cervical Cancer Risk Factors for Biopsy: This Dataset is Obtained from UCI Repository and kindly acknowledged! This file contains a List of Risk Factors for Cervical Cancer leading to a Biopsy Examination! About 11,000 new cases of invasive cervical cancer are diagnosed each year in the U.S. However, the number of new cervical cancer cases has been declining steadily over the past decades. Although it is the most preventable type of cancer, each year cervical cancer kills about 4,000 women in the U.S. and about 300,000 women worldwide. In the United States, cervical cancer mortality rates plunged by 74% from 1955 - 1992 thanks to increased screening and early detection with the Pap test. AGE Fifty percent of cervical cancer diagnoses occur in women ages 35 - 54, and about 20% occur in women over 65 years of age. The median age of diagnosis is 48 years. About 15% of women develop cervical cancer between the ages of 20 - 30. Cervical cancer is extremely rare in women younger than age 20. However, many young women become infected with multiple types of human papilloma virus, which then can increase their risk of getting cervical cancer in the future. Young women with early abnormal changes who do not have regular examinations are at high risk for localized cancer by the time they are age 40, and for invasive cancer by age 50. SOCIOECONOMIC AND ETHNIC FACTORS Although the rate of cervical cancer has declined among both Caucasian and African-American women over the past decades, it remains much more prevalent in African-Americans -- whose death rates are twice as high as Caucasian women. Hispanic American women have more than twice the risk of invasive cervical cancer as Caucasian women, also due to a lower rate of screening. These differences, however, are almost certainly due to social and economic differences. Numerous studies report that high poverty levels are linked with low screening rates. In addition, lack of health insurance, limited transportation, and language difficulties hinder a poor woman’s access to screening services. HIGH SEXUAL ACTIVITY Human papilloma virus (HPV) is the main risk factor for cervical cancer. In adults, the most important risk factor for HPV is sexual activity with an infected person. Women most at risk for cervical cancer are those with a history of multiple sexual partners, sexual intercourse at age 17 years or younger, or both. A woman who has never been sexually active has a very low risk for developing cervical cancer. Sexual activity with multiple partners increases the likelihood of many other sexually transmitted infections (chlamydia, gonorrhea, syphilis).Studies have found an association between chlamydia and cervical cancer risk, including the possibility that chlamydia may prolong HPV infection. FAMILY HISTORY Women have a higher risk of cervical cancer if they have a first-degree relative (mother, sister) who has had cervical cancer. USE OF ORAL CONTRACEPTIVES Studies have reported a strong association between cervical cancer and long-term use of oral contraception (OC). Women who take birth control pills for more than 5 - 10 years appear to have a much higher risk HPV infection (up to four times higher) than those who do not use OCs. (Women taking OCs for fewer than 5 years do not have a significantly higher risk.) The reasons for this risk from OC use are not entirely clear. Women who use OCs may be less likely to use a diaphragm, condoms, or other methods that offer some protection against sexual transmitted diseases, including HPV. Some research also suggests that the hormones in OCs might help the virus enter the genetic material of cervical cells. HAVING MANY CHILDREN Studies indicate that having many children increases the risk for developing cervical cancer, particularly in women infected with HPV. SMOKING Smoking is associated with a higher risk for precancerous changes (dysplasia) in the cervix and for progression to invasive cervical cancer, especially for women infected with HPV. IMMUNOSUPPRESSION Women with weak immune systems, (such as those with HIV / AIDS), are more susceptible to acquiring HPV. Immunocompromised patients are also at higher risk for having cervical precancer develop rapidly into invasive cancer. DIETHYLSTILBESTROL (DES) From 1938 - 1971, diethylstilbestrol (DES), an estrogen-related drug, was widely prescribed to pregnant women to help prevent miscarriages. The daughters of these women face a higher risk for cervical cancer. DES is no longer prsecribed.

As of 2022, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer, and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around ******* never used sunscreen.

This data shows premature deaths (Age under 75) from all Cancers, numbers and rates by gender, as 3-year moving-averages. Cancers are a major cause of premature deaths. Inequalities exist in cancer rates between the most deprived areas and the most affluent areas. Directly Age-Standardised Rates (DASR) are shown in the data (where numbers are sufficient) so that death rates can be directly compared between areas. The DASR calculation applies Age-specific rates to a Standard (European) population to cancel out possible effects on crude rates due to different age structures among populations, thus enabling direct comparisons of rates. A limitation on using mortalities as a proxy for prevalence of health conditions is that mortalities may give an incomplete view of health conditions in an area, as ill-health might not lead to premature death. Data source: Office for Health Improvement and Disparities (OHID), indicator ID 40501, E05a. This data is updated annually.

ABSTRACT OBJECTIVE To analyze inequalities in incidence, mortality, and estimated survival for neoplasms in men according to social vulnerability. METHODS Analysis of cases and deaths of all neoplasms and the five most common in men aged 30 years or older in the city of Campinas (SP), between 2010 and 2014, using data from the Population-Based Cancer Registry (RCBP) and the Mortality Information System (SIM). The areas of residence were grouped into five social vulnerability strata (SVS) using São Paulo Social Vulnerability Index. For each SVS, age-standardized incidence and mortality rates were calculated. A five-year survival proxy was calculated by complementing the ratio of the mortality rate to the incidence rate. Inequalities between strata were measured by the ratios between rates, the relative inequality index (RII) and the angular inequality index (AII). RESULTS RII revealed that the incidence of all neoplasms (0.66, 95%CI 0.62–0.69) and colorectal and lung cancers were lower among the most socially vulnerable, who presented a higher incidence of stomach and oral cavity cancer. Mortality rates for stomach, oral cavity, prostate and all types of cancer were higher in the most vulnerable segments, with no differences in mortality for colorectal and lung cancer. Survival was lower in the most social vulnerable stratum for all types of cancer studied. AII showed excess cases in the least vulnerable and deaths in the most vulnerable. Social inequalities were different depending on the tumor location and the indicator analyzed. CONCLUSION There is a trend of reversal of inequalities between incidence-mortality and incidence-survival, and the most social vulnerable segment presents lower survival rates for the types of cancer, pointing to the existence of inequality in access to early diagnosis and effective and timely treatment.

IntroductionThe COVID-19 pandemic has considerably affected healthcare systems worldwide and is expected to influence cancer incidence, mortality, stage at diagnosis, and survival. This study aimed to assess COVID-19-related changes in cancer incidence observed in 2020 in the Greater Poland region.Materials and methodsData from the Greater Poland Cancer Registry on cancer patients diagnosed between 2010 and 2020 were analysed. To quantify the change in the number of incident cancer cases during the COVID-19 pandemic, we calculated the standardized incidence ratio (SIR) and the incidence rate difference (IRD) to assume the pandemic-attributable gap in cancer incidence.ResultsIn 2020, in Greater Poland, the expected number of new cancer cases was 18 154 (9 226 among males and 8 927 among females), while the observed number was 14 770 (7 336 among males and 7 434 among females). The registered number of cancer cases decreased in 2020 by 20% (SIR 0·80, 95% CI 0·78 to 0·81) and 17% (SIR 0·83, 95% CI 0·81 to 0·85) in males and females, respectively. Among men, the most significant difference was reported for myeloma (SIR 0·59, 95% CI 0·45 to 0·77), among women for bone cancer (SIR 0·47, 95% CI 0·20 to 0·93). In females the observed incidence was higher than expected for cancer of an unspecified site (SIR 1·19, 95% CI 1·01 to 1·38). In our study, the decrease in new cancer cases was greater in males than in females.DiscussionThe observed incidence was affected in most cancer sites, with the most significant deviation from the expected number in the case of myeloma. An increase in the observed incidence was reported only in women diagnosed with cancer of an unspecified site, which might reflect shortages in access to oncological diagnostics.